Bionomics Limited/fi 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Neuphoria Therapeutics Inc. reports progress in its clinical pipeline for neuropsychiatric disorders, including BNC210 in Phase 3 for SAD and Phase 2b/3 for PTSD, alongside a $15 million milestone payment from Merck.
Bionomics Limited has released its Code of Business Conduct policy and filed its annual report on Form 10-K, outlining its commitment to ethical practices and providing a detailed overview of its financial and operational status.